We have developed a novel, immunotherapeutic tool for inhibiting T-cellmediated pathology, namely tolerogenic dendritic cells (tolDC) (2) (3) (4) (5) (6) . TGF-β is a pleiotropic cytokine, produced by a wide variety of cells. Its most immunologically relevant and potent isoform is TGF-β1, which plays an important role in immunoregulation via direct suppression of T-cell proliferation and cytokine production (8) and the induction of FoxP3 + Tregs (9) . TGF-β1 is produced in a latent inactive form through non-covalent linkage to latencyassociated peptide (LAP) (10) . LAP(TGF-β1) can bind to the surface of cells, components of the extracellular matrix, or can exist in a soluble form. LAP(TGF-β1) is activated (released from LAP) by a number of mechanisms, such as cleavage by thrombospondin. Activated TGF-β1 binds to TGF-β receptor II (TGF-βRII) followed by recruitment and activation of the primary signal transducer, TGF-βRI (ALK5). This leads to phosphorylation of the receptorregulated Smads, Smad2 and Smad3, that regulate target gene transcription (11) . Negative feedback of the pathway is mediated by the inhibitory Smad, Smad7, which can either block or degrade TGF-βRI (12) .
TGF-β1 is abundant in the affected joints of RA patients (13) (14) (15) (16) (17) (18) (19) and increases with disease duration (20) . However, this high level of TGF-β1 does not adequately regulate the pathogenic T-cell response in RA. This may be due to the overall proinflammatory cytokine environment in the synovium and the high level of T-cell activation, which are known to downregulate TGF-βRII expression (21, 22) or, alternatively, may be due to induction of inhibitory molecules, such as Smad7 (23) .
We aimed to determine a potential role for TGF-β1 in the regulatory function of tolDC, and more specifically to investigate the ability of tolDC to regulate CD4 + T-cells from RA patients in a TGF-β1-dependent manner. A more complete understanding of the molecular mechanisms by which tolDC regulate T-cell responses is essential for the development of future studies on tolDC immunotherapy for RA.
Materials and methods
The minimum information about tolerogenic antigen-presenting cells (MITAP) checklist was followed for the preparation of this manuscript (24) . See http://w3id.org/ontolink/mitap for MITAP document and checklist.
Isolation of cells from peripheral blood and synovial fluid
Human samples were obtained from healthy controls (HC) and patients with RA 
Generation of DC populations
Freshly isolated monocytes were immediately cultured in RPMI-1640 (Sigma, Poole, UK) supplemented with 10% FCS (Lonza, Basel, Switzerland), 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (all from Sigma) at 0.5x10 6 cells/ml in a 1 ml volume in a 24-well culture plate (costar, Corning, NY, USA) in the presence of IL-4 and GM-CSF (50 ng/ml each, Immunotools, Friesoythe, Germany) for 7 days at 37 o C with 5% CO2. Fresh pre-warmed medium and cytokines were added on day 3. Mature DC (matDC) were matured on day 6 by addition of LPS from Escherichia coli (0.1μg/ml, Sigma) for 24 h. tolDC were generated as above but with by addition of Dex (1x10 -6 M, Sigma) at day 3 and Dex (1x10 M, Leo-Pharma, Ballerup, Denmark) and LPS (0.1 μg/ml) at day 6 for 24 h. On day 7 tolDC and matDC morphology was checked using an inverted microscope -tolDC were slightly elongated and adhered to the culture plates, whereas matDC were more rounded with visable dendrites and did not adhere to the culture plates. All DC populations were extensively washed before using them in functional assays. DC phenotype was checked using flow cytometry and was consistent with tolDC exhibiting a semi-mature phenotype, expressing low levels of CD83, intermediate levels of CD80 and CD86 and high levels of HLA-DR (data not shown).
Micro Fluidic Cards
RNA was extracted from DC using an RNeasy kit (Qiagen, Crawley, UK). RNA was reverse-transcribed to cDNA using random hexamers and SuperScript II 
T-cell restimulation

Statistics
Wilcoxon signed rank tests or Mann Whitney tests were performed using Prism 4.0 (GraphPad Software). All p values are two-tailed.
Results tolDC express TGF-β1
To investigate the role of TGF-β1 in tolDC function we began by measuring the expression of TGF-β1 in tolDC and matDC populations. tolDC expressed more TGFB1 mRNA than matDC ( Figure 1A ). To confirm that TGFB1 transcripts were translated, we used flow cytometry to assess TGF-β1 protein expression on the cell surface using an anti-LAP(TGF-β1) antibody. Mirroring the transcript data, LAP(TGF-β1) was expressed at a higher level on the surface of tolDC as compared to matDC ( Figure 1B) . Together, these data show that tolDC express a higher level of TGF-β1 than matDC at both mRNA and protein level.
TGF-β1 is involved in tolDC regulatory function
We next determined the role of TGF-β1 in the regulatory action of tolDC.
Allogeneic HC CD4 + T-cells were co-cultured with DC in the presence or absence of SB-505124, a small molecule inhibitor of TGF-βRI. In keeping with our previous finding(4), tolDC showed a reduced ability to induce T-cell proliferation and IFN-γ production in CD4 + T-cells as compared with matDC ( Figure 2A-B) . Importantly, addition of SB-505124 had no effect on T-cell proliferation but enhanced the production of IFN-γ by tolDC-primed T-cells in a dose-dependent manner -restoring levels to those produced by control cells (matDC-primed T cells) (Figure 2A-B) . The effect of blocking TGF-β1 signalling in a primary MLR using 1μM SB-505124 results in a 2.7 fold increase in IFN-γ production from matDC-CD4 We previously investigated the effect of blocking TGF-β1 signalling in tolDC-Tcell co-cultures and demonstrated that the use of a TGF-β1 neutralising antibody (1D11, R&D Systems) had no effect on the regulatory action of tolDC (2) . The discrepancy between the results with the neutralising antibody and those shown here using the ALK5 inhibitor SB-505124, or LAP, may be explained by the concentration of neutralising antibody used being insufficient to inhibit the amount of TGF-β1 produced by tolDC. In addition, FCS, which contains high levels of TGF-β1, was added to the culture medium in the original experiments. This may have led to sequestration of the neutralising antibody, thus interfering with efforts to neutralise TGF-β1 in those assays.
We report that TGF-β1 has differential effects on CD4 + T-cell proliferation and cytokine production: there was no effect on proliferation but potent inhibition of cytokine production. TGF-β1 can have both stimulatory and inhibitory effects on T-cell proliferation and differentiation depending on the differentiation stage of the cells and the cytokine microenvironment. It has been reported that TGF-β1 can inhibit resting CD4 + T-cell proliferation and cytokine production but has no inhibitory effect on activated T-cells, due to downregulation of TGF-βRII (22) . Figure 5) and enhancing the level of Smad2/3-mediated signalling will require further investigation.
In conclusion, tolDC regulate T-cell cytokine production via expression of TGF- PBMC from HC (n=6) and PBMC and SFMC from RA patients (n=5) were stimulated with αCD3αCD28 beads in the absence or presence of 10 ng/ml TGF-β1 for 3 days. IFN-γ was measured by ELISA. Horizontal lines represent median values. * p < 0.05 calculated using a Wilcoxon signed rank test. Figure 3B shows these results depicted as the percentage suppression of cultures containing TGF-β1 compared to those without. 
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